GOLGA5

Across TCGA pan-cancer cohorts, GOLGA5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GOLGA5 data layer compared with 21 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GOLGA5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GOLGA5 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where GOLGA5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.540	0.172	.003	13	view →
LSCC	DFS	Median	II,III,IV	0.485	1.000	.006	5	view →
LUAD	DFS	Tertile	All	0.375	0.746	.031	4	view →
CCRCC	DFS	Median	All	1.000	0.724	.014	4	view →
HNSC	DFS	Tertile	II,III,IV	0.901	0.740	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GOLGA5–PDAC (DFS)

Open the PDAC breakdown →